Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASND NASDAQ:AXSM NASDAQ:BBIO NASDAQ:NAMS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$223.29+2.4%$232.03$160.86▼$250.74$13.60B0.39543,380 shs638,053 shsAXSMAxsome Therapeutics$253.40-0.7%$212.64$96.09▼$257.92$13.13B0.61631,470 shs628,287 shsBBIOBridgeBio Pharma$68.00+1.8%$70.12$39.63▼$84.94$13.08B0.982.66 million shs3.09 million shsNAMSNewAmsterdam Pharma$30.60+0.7%$33.39$17.63▼$42.21$3.55B0.071.27 million shs694,915 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S+2.40%+8.49%-7.16%-2.09%+30.73%AXSMAxsome Therapeutics-0.69%+7.77%+11.28%+57.23%+143.42%BBIOBridgeBio Pharma+1.80%+0.94%+2.83%-4.14%+70.94%NAMSNewAmsterdam Pharma+0.66%-1.13%-13.66%0.00%+51.41%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$223.29+2.4%$232.03$160.86▼$250.74$13.60B0.39543,380 shs638,053 shsAXSMAxsome Therapeutics$253.40-0.7%$212.64$96.09▼$257.92$13.13B0.61631,470 shs628,287 shsBBIOBridgeBio Pharma$68.00+1.8%$70.12$39.63▼$84.94$13.08B0.982.66 million shs3.09 million shsNAMSNewAmsterdam Pharma$30.60+0.7%$33.39$17.63▼$42.21$3.55B0.071.27 million shs694,915 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S+2.40%+8.49%-7.16%-2.09%+30.73%AXSMAxsome Therapeutics-0.69%+7.77%+11.28%+57.23%+143.42%BBIOBridgeBio Pharma+1.80%+0.94%+2.83%-4.14%+70.94%NAMSNewAmsterdam Pharma+0.66%-1.13%-13.66%0.00%+51.41%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 3.00Buy$295.3932.29% UpsideAXSMAxsome Therapeutics 2.95Moderate Buy$256.791.34% UpsideBBIOBridgeBio Pharma 2.85Moderate Buy$89.5931.75% UpsideNAMSNewAmsterdam Pharma 2.83Moderate Buy$48.6058.82% UpsideCurrent Analyst Ratings BreakdownLatest NAMS, ASND, BBIO, and AXSM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026AXSMAxsome Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$380.006/11/2026AXSMAxsome Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeReduce ➝ Overweight6/9/2026ASNDAscendis Pharma A/S OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/4/2026AXSMAxsome Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/3/2026BBIOBridgeBio Pharma Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$104.005/28/2026BBIOBridgeBio Pharma Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$94.00 ➝ $98.005/28/2026BBIOBridgeBio Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$110.005/26/2026BBIOBridgeBio Pharma Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/19/2026BBIOBridgeBio Pharma CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$82.005/18/2026ASNDAscendis Pharma A/S CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$355.005/18/2026ASNDAscendis Pharma A/S CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy ➝ Strong-Buy(Data available from 6/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$814.57M17.10N/AN/A($2.97) per share-75.18AXSMAxsome Therapeutics$638.50M20.42N/AN/A$1.75 per share144.80BBIOBridgeBio Pharma$502.08M26.53N/AN/A($10.77) per share-6.31NAMSNewAmsterdam Pharma$22.50M158.98N/AN/A$5.97 per share5.13Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$258M$8.6725.7520.79N/A57.87%N/A-8.37%8/6/2026 (Estimated)AXSMAxsome Therapeutics-$183.17M-$3.73N/A50.58N/A-26.59%-267.16%-28.53%8/3/2026 (Estimated)BBIOBridgeBio Pharma-$724.93M-$3.74N/A295.65N/A-124.42%N/A-65.81%8/4/2026 (Estimated)NAMSNewAmsterdam Pharma-$203.82M-$1.79N/AN/AN/A-943.23%-26.49%-24.37%8/5/2026 (Estimated)Latest NAMS, ASND, BBIO, and AXSM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026ASNDAscendis Pharma A/S$0.21$0.32+$0.11$11.29$362.47 million$285.45 million5/7/2026Q1 2026BBIOBridgeBio Pharma-$0.70-$0.84-$0.14-$0.84$178.07 million$194.52 million5/7/2026Q1 2026NAMSNewAmsterdam Pharma-$0.46-$0.40+$0.06-$0.40$1.75 million$3.04 million5/4/2026Q1 2026AXSMAxsome Therapeutics-$0.85-$1.26-$0.41-$1.26$191.10 million$191.20 million3/31/2026Q1 2026NAMSNewAmsterdam PharmaN/A-$0.40N/A-$0.40N/A$3.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/AAXSMAxsome TherapeuticsN/AN/AN/AN/AN/ABBIOBridgeBio PharmaN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/S0.791.000.72AXSMAxsome Therapeutics2.271.391.32BBIOBridgeBio PharmaN/A1.521.48NAMSNewAmsterdam PharmaN/A9.769.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/AAXSMAxsome Therapeutics81.49%BBIOBridgeBio Pharma99.85%NAMSNewAmsterdam Pharma89.89%Insider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%AXSMAxsome Therapeutics20.60%BBIOBridgeBio Pharma14.23%NAMSNewAmsterdam Pharma12.74%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S1,18962.38 million37.43 millionOptionableAXSMAxsome Therapeutics38051.46 million40.86 millionOptionableBBIOBridgeBio Pharma400195.86 million167.99 millionOptionableNAMSNewAmsterdam Pharma4116.90 million102.01 millionOptionableNAMS, ASND, BBIO, and AXSM HeadlinesRecent News About These CompaniesA Look At NewAmsterdam Pharma (NAMS) Valuation After Recent Share Price WeaknessJune 11, 2026 | finance.yahoo.comNewAmsterdam Pharma Company N.V. (NAMS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 10, 2026 | seekingalpha.comCapital World Investors Raises Stock Holdings in NewAmsterdam Pharma Company N.V. $NAMSJune 9, 2026 | marketbeat.comBillionaire Stanley Druckenmiller Likes This Small-Cap Pharma Stock in 2026June 8, 2026 | insidermonkey.comNewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific SessionsJune 3, 2026 | globenewswire.comJTC Employer Solutions Trustee Ltd Purchases Shares of 75,500 NewAmsterdam Pharma Company N.V. $NAMSMay 29, 2026 | marketbeat.comNewAmsterdam Pharma to Participate at Upcoming Investor Conferences in JuneMay 28, 2026 | globenewswire.comSwedbank AB Buys Shares of 90,900 NewAmsterdam Pharma Company N.V. $NAMSMay 28, 2026 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 65,000 SharesMay 28, 2026 | insidertrades.comLisanti Capital Growth LLC Buys 131,965 Shares of NewAmsterdam Pharma Company N.V. $NAMSMay 24, 2026 | marketbeat.comNewAmsterdam Pharma Company N.V. $NAMS Holdings Boosted by Legato Capital Management LLCMay 23, 2026 | marketbeat.comNewAmsterdam Pharma Company N.V.May 21, 2026 | edition.cnn.comNewAmsterdam Pharma Company N.V. (NAMS) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comNewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Reported Earnings Last Week And Analysts Are Already Upgrading Their EstimatesMay 12, 2026 | finance.yahoo.comNewAmsterdam Pharma Company N.V. (NAMS) Discusses Clinical Development Update and Interim Analysis Plans for PREVAIL Trial - SlideshowMay 11, 2026 | seekingalpha.comNewAmsterdam Pharma to Participate at Upcoming Investor Conferences in MayMay 11, 2026 | globenewswire.comNewAmsterdam Pharma Company N.V. (NAMS) Discusses Clinical Development Update and Interim Analysis Plans for PREVAIL Trial TranscriptMay 9, 2026 | seekingalpha.comDo NewAmsterdam Pharma’s (NAMS) Dilution Plans Reframe Its Path to Funding Ongoing Losses?May 8, 2026 | finance.yahoo.comNewAmsterdam Pharma Company NV (NAMS) reports Q1 loss, tops revenue estimatesMay 8, 2026 | msn.comNewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue EstimatesMay 7, 2026 | zacks.comNewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial ResultsMay 7, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNAMS, ASND, BBIO, and AXSM Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$223.29 +5.23 (+2.40%) Closing price 06/15/2026 04:00 PM EasternExtended Trading$223.41 +0.12 (+0.05%) As of 06/15/2026 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Axsome Therapeutics NASDAQ:AXSM$253.40 -1.77 (-0.69%) Closing price 06/15/2026 04:00 PM EasternExtended Trading$251.52 -1.88 (-0.74%) As of 06/15/2026 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.BridgeBio Pharma NASDAQ:BBIO$68.00 +1.20 (+1.80%) Closing price 06/15/2026 04:00 PM EasternExtended Trading$67.30 -0.70 (-1.02%) As of 06/15/2026 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.NewAmsterdam Pharma NASDAQ:NAMS$30.60 +0.20 (+0.66%) Closing price 06/15/2026 04:00 PM EasternExtended Trading$30.73 +0.13 (+0.44%) As of 06/15/2026 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas What's Behind the Social Media Controversy Surrounding IonQ? Mission Control: Floating In SpaceX's Record-Breaking Orbit 3 Dividend Increases Investors Can Actually Trust RH’s Strong Q1 Still Leaves Investors With One Big Question SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
